Aadi Bioscience, Inc.
General ticker "AADI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $55.0M (TTM average)
Aadi Bioscience, Inc. follows the US Stock Market performance with the rate: 44.3%.
Estimated limits based on current volatility of 4.3%: low 1.60$, high 1.74$
Factors to consider:
- Earnings for 12 months up through Q4 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [1.79$, 5.30$]
- 2024-12-30 to 2025-12-30 estimated range: [2.32$, 6.13$]
Financial Metrics affecting the AADI estimates:
- Negative: Non-GAAP EPS, $ of -2.44 <= 0.04
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -35.19 <= 1.79
- Negative: negative Net income
- Negative: Industry operating cash flow per share per price (median), % of -24.70 <= 2.82
- Negative: Shareholder equity ratio, % of 79.44 > 63.75
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term AADI quotes
Long-term AADI plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $1.00MM | $15.22MM | $24.35MM |
| Operating Expenses | $112.22MM | $77.90MM | $96.29MM |
| Operating Income | $-111.22MM | $-62.68MM | $-71.93MM |
| Non-Operating Income | $1.13MM | $2.17MM | $6.17MM |
| Interest Expense | $0.67MM | $0.23MM | $0.23MM |
| R&D Expense | $19.67MM | $32.66MM | $48.93MM |
| Income(Loss) | $-110.09MM | $-60.51MM | $-65.77MM |
| Taxes | $0.00MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $-110.09MM | $-57.01MM | $-65.77MM |
| Stockholders Equity | $136.41MM | $158.38MM | $105.19MM |
| Inventory | $0.00MM | $1.86MM | $6.43MM |
| Assets | $157.91MM | $184.24MM | $132.42MM |
| Operating Cash Flow | $-22.42MM | $-49.64MM | $-59.66MM |
| Capital expenditure | $0.05MM | $0.44MM | $3.97MM |
| Investing Cash Flow | $25.15MM | $-132.89MM | $83.21MM |
| Financing Cash Flow | $141.80MM | $72.62MM | $0.33MM |
| Earnings Per Share** | $-12.34 | $-2.53 | $-2.44 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.